A Study of BGM-2121 in Patients With Advanced Solid Tumors

This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.

Inclusion Criteria: 1. With either gender aged ≥ 18 years, 2. Has a confirmed diagnosis of advanced solid tumor(s), 3. The subject has received and failed standard-of-care anti-cancer therapy 4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 5. ... Exclusion Criteria: 1. Has any ongoing toxicity from previous anti-cancer treatments 2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s) 3. History of another primary malignancy within the last three years 4. ...